Reckitt Restructure Seeks To Maximize Dietary Supplement Growth
Executive Summary
Reckitt has identified “lots of growth spaces and lots of growth potential” for its vitamins, minerals and supplements business, which it will seek to capitalize on by moving the operation to its OTC-focused Health unit.
You may also be interested in...
Reckitt Records Impairment Charge For Biofreeze
Reckitt recorded a £152m impairment charge for Biofreeze in 2022 after the topical pain relief brand underperformed in the first half of the year. Despite issues for Biofreeze, Reckitt's Health business as a whole had a strong showing over the 12 months, with sales jumping by 19%.
Reckitt Seeing Softening VMS Demand As OTC Remains Resilient
While sales remain strong for its cold and flu brands as the winter illness season gets underway, Reckitt is seeing demand soften for its dietary supplements as consumers rein in spending on more discretionary categories. This has not, however, had a major impact on Reckitt's Health business, which posted sales up 19% in Q3.
Euro Q2 Consumer Health Earnings Preview: Volatility, Delay, Upturn And Goodbye
Major Europe-based consumer health players Bayer, Sanofi, Reckitt and GSK feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2022 results over the coming weeks.